Document is current

Article History

Received: 11 August 2023

Accepted: 28 March 2024

First Online: 18 April 2024

Declarations

:

: NL, NM, and VB have nothing to declare. <i>N</i>–<i>P</i> E is an employee at Takeda. OO has been PI on projects at Karolinska Institutet, partly financed by investigator-initiated grants from Janssen and Ferring, and Karolinska Institutet has received fees for lectures and participation on advisory boards from Janssen, Ferring, Takeda, and Pfizer. OO also reports a grant from Pfizer in the context of a national safety monitoring program. JFL has coordinated a study on behalf of the Swedish IBD quality register (SWIBREG), which received funding from Janssen. HH has served as a speaker, consultant or advisory board member: AbbVie, Janssen, Pfizer, Takeda, Tillotts Pharma, Vifor Pharma, and received grant support from Ferring and Tillotts Pharma. JM has served as a speaker, consultant or advisory board member for AbbVie, Bayer, BMS, Hospira, Janssen, MSD, Pfizer, Sandoz, Takeda, and UCB, and has received grant support from AbbVie, Calpro AS, Fresenius Kabi, Pfizer, SVAR Life Science, and Takeda. CE reports grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer, Abbvie. JH has served as speaker, consultant and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Ferring, Galapagos, Gilead, Hospira, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc, Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, and Vifor Pharma. JH also has received grant support from Janssen, MSD and Takeda.

: This study was approved by the Swedish Ethical review Authority (2014/375-31 and 2020-05060).